Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Belimumab in Idiopathic CD4 Lymphopenia (Phoebe)
NCT04097561Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2020
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of belimumab in idiopathic CD4 lymphocytopenia (ICL), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Incidence of adverse events (AEs) related to belimumab at 48 weeks. Started Jan 2020; status: recruiting.
02
Drugs
belimumab
03
Conditions
idiopathic CD4 lymphocytopenia (ICL)
Beyond the preview
Go deeper on NCT04097561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097561.